Pharma & Biotech Global Week in Review 9 Apr 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

US CAFC clarifies obviousness standard in context of cDNA cloning invention: In re Kubin (Holman’s Biotech IP Blog) (Patent Docs) (Hal Wegner) (Philip Brooks’ Patent Infringement Updates) (Patently-O) (Patent Docs)

Xigris (Drotrecogin alfa) –US: CAFC: Pioneering claims require more expansive written description: Ariad v Eli Lilly (Patently-O) (Patent Docs) (Hal Wegner) (Patent Docs) (Holman’s Biotech IP Blog)

Axura (Memantine) – UK: Questions on interpretation of Article 2 SPC Regulation slow down fast tracked patent dispute: Synthon BV v Merz Pharma GmbH & Co KGaA (The SPC Blog) (PatLit) (IPKat)

 
General

Office of the High Commission for Human Rights turns eye to health and IP (Intellectual Property Watch)

Officials working informally toward May consensus on avian flu preparedness (Intellectual Property Watch)

Enzymes a potential planet-saver, but heavy patenting necessary, industry says (Intellectual Property Watch)

Rationality of a patent pool (IP Frontline)

Argentina: Judicial decision in Argentina tackles interplay between enforcing patent rights and antitrust law in dispute between Monsanto and Argentine government over ‘GM soy-ready RR’ (Moeller IP)

Australia: Pharmaceutical manufacture for export – what do you think? (IP Think Tank)

Brazilian public-private partnerships in the pharma industry (IP tango)

EU: ECJ to rule on reference on SPC Regulation interpretation from Lithuania in Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras (The SPC Blog)

India: Delhi High Court Dasatinib order: Is patent-drug regulatory linkage a necessity? (Part I – Patent Circle) (Part II – Patent Circle)

Indian biogenerics on an upswing – US Promoting Innovation and Access to Life-Saving Medicine Act (Patent Baristas)

US: Anti-reverse payment legislation Protecting Consumer Access to Generic Drugs Act of 2009 introduced in the House (Patent Docs)

US: CAFC clarifies obviousness standard in context of cDNA cloning invention: In re Kubin (Holman’s Biotech IP Blog) (Patent Docs) (Hal Wegner) (Philip Brooks’ Patent Infringement Updates) (Patently-O) (Patent Docs)

US: Ariad v Eli Lilly and In re Kubin: One Federal Circuit panel perpetuates the Lilly written description doctrine, while another avoids addressing it (Holman’s Biotech IP Blog)

US: Reference with unknown utility still anticipates: In re Gleave (Patently-O)

CAFC upholds district court finding that Third Wave Technology did not infringe Digene’s patent covering test for human papillomavirus; dismisses Third Waves’ antitrust counterclaims (Law360) (Patent Docs)

US: Applying pediatric exclusivity after product approval; FDA interpretations about which you might not be aware (FDA Law Blog)

 
Products

Androgel (Testosterone) – US: Antitrust class action complaint filed against Androgel manufacturers Unimed, Solvay, Watson, Par and Paddock (SmartBrief) (GenericsWeb)

Aspirin – Poland: Polish Patent Office dismisses Bayer’s request to invalidate Zakłady Farmaceutyczne Polpharma’s PLUSPIRYNA trade mark registration (Class 46)

Atripla (Efavirenz/Emtricitabine/Tenofovir) – US: Teva files para IV challenge to Gilead’s patents covering Emtricitabine (SmartBrief) (GenericsWeb)

Axura (Memantine) – Netherlands Patent Office denies Synthon’s request to revoke or revise date of SPC relating to Memantine (The SPC Blog)

Axura (Memantine) – UK: Questions on interpretation of Article 2 SPC Regulation slow down fast tracked patent dispute: Synthon BV v Merz Pharma GmbH & Co KGaA (The SPC Blog) (PatLit) (IPKat)

Cardene (Nicardipine) – US: District Court New Jersey: Sun’s Carden ANDA infringes EKR patent (Law360)

Clarinex (Desloratadine) – US: Mylan, Schering-Plough enter settlement agreement relating to Clarinex patent dispute; agreement subject to DoJ and FTC review (SmartBrief) (Law360)

Combigan (Brimonidine/Timolol) – US: Allergan sues Sandoz over generic Combigan ANDA (Law360)

Concerta (Methylphenidate) – US: District Court Delaware rules Watson’s generic Concerta would not infringe Johnson & Johnson patents (Law360)

Ethyol (Amifostine) – US: Both parties, MedImmune Oncology and Sun Pharma’s summary judgment motions shot down in Ethyol patent suit (Law360)

Fentora (Fentanyl) – US: Watson loses bid to toss suit over Fentora ANDA brought by Cephalon (Law360)

Fosrenol (Lanthanum) – US: Shire sues Natco over ANDA for Fosrenol (Law360) (Patent Docs)

Integrilin (Eptifibatide) – US: Millenium files patent infringement suit against Teva over generic Integrilin ANDA (Patent Docs)

Lexapro (Escitalopram) – Canada: Escitalopram patent not a selection patent; Minister prohibited from issuing Notices of Compliance to respondents prior to patent expiry: Lundbeck v Cobalt, Genpharm and Apotex (Pharmacapsules @ Gowlings)

Lexapro (Escitalopram) – Netherlands: Escitalopram patent/SPC held invalid in the Hague District Court: ratiopharm et al v Lundbeck (The SPC Blog)

Maxipime (Cefepime) – Canada: Patent covering polymorph of Cefepime not anticipated, but obvious: Bristol-Myers Squibb v Apotex (Pharmacapsules @ Gowlings)

OxyContin (Oxycodone) – UK: EWHC: Sustained release OxyContin patent sustained: Napp Pharmaceutical Holdings Ltd v ratiopharm GmbH/Napp Pharmaceutical Holdings Ltd v Sandoz Ltd (Hal Wegner) (IPKat) (Law360)

Plavix (Clopidogrel) – US: Former Bristol-Myers Squibb senior executive pleads guilty for role in dishonest dealings with federal government relating to Plavix patent deal (SmartBrief) (Law360)

Pulmicort (Budesonide) – US: AstraZeneca tries to block Apotex launch of generic version of children’s asthma medication (Law360) (GenericsWeb)

Renvela (Sevelamer) – US: Impax files para IV challenge against Genzyme’s Renvela patents (SmartBrief) (Patent Docs) (Law360) (GenericsWeb)

Seroquel (Quetiapine) – US: Biovail counterclaims accuse AstraZeneca of inequitable conduct in patent battle over Seroquel (Law360)

Xigris (Drotrecogin alfa) –US: CAFC: Pioneering claims require more expansive written description: Ariad v Eli Lilly (Patently-O) (Patent Docs) (Hal Wegner) (Patent Docs)

Zemplar (Paricalcitol) – US: Abbott files patent infringement suit against Sandoz over generic Zemplar ANDA (Patent Docs)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: